Originally published by our sister publication Specialty Pharmacy Continuum
By Myles Starr
Cytokine release syndrome (CRS) is the most commonly observed adverse event associated with chimeric antigen receptor T-cell (CAR-T) therapy. However, true rates of CRS have been difficult to ascertain due to the small sample sizes of CAR-T therapy clinical trials. A new analysis based on Medicare data may offer a more reliable picture of CRS occurrence—and road map for strategies to prevent it.
